← Back to Search

Monoclonal Antibodies

OS2966 for Malignant Glioma

Phase 1
Waitlist Available
Research Sponsored by OncoSynergy, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

This trial tests OS2966, a new antibody medicine, in adults with recurring or worsening high-grade brain tumors. The medicine is delivered directly to the tumor using a special technique to bypass the brain's protective barrier, aiming to stop cancer cells from growing and spreading.

Eligible Conditions
  • Malignant Glioma
  • Brain Tumor
  • Glioblastoma
  • Anaplastic Astrocytoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Optimal Biological Dose
Secondary study objectives
Spatial Distribution of OS2966 when delivered via CED
Tumor Response Rate

Trial Design

1Treatment groups
Experimental Treatment
Group I: Direct Infusion of OS2966Experimental Treatment2 Interventions
OS2966 will be directly infused into the brain tumor and surrounding tumor infiltrated brain via convection-enhanced delivery
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gadoteridol
2023
Completed Phase 3
~750

Find a Location

Who is running the clinical trial?

OncoSynergy, Inc.Lead Sponsor
Infuseon Therapeutics, Inc.Industry Sponsor
3 Previous Clinical Trials
12 Total Patients Enrolled
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top